TIM
LGND icon

Tortoise Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Tortoise Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-102
Closed -$18.1K – 892
2025
Q3 		$18.1K Buy
102
+2
+2% +$297 ﹤0.01% 536
2025
Q2 		$11.4K Hold
100
– – ﹤0.01% 591
2025
Q1 		$10.5K Hold
100
– – ﹤0.01% 583
2024
Q4 		$10.7K Hold
100
– – ﹤0.01% 626
2024
Q3 		$10K Buy
+100
New +$10.1K ﹤0.01% 641

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Tortoise Investment Management's LGND Position: Q4 2025 in Review

Tortoise Investment Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2025, closing a stake of 102 shares — an estimated $18.1K sold.

Tortoise Investment Management first reported a position in LGND in Q3 2024 and held it in 5 quarters. The position peaked at $18.1K in Q3 2025. 350 funds tracked by Wall St. Rank hold LGND as of Q4 2025.

  • Tortoise Investment Management reported no remaining Ligand Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Tortoise Investment Management sold 102 Ligand Pharmaceuticals shares in Q4 2025, an estimated $18.1K.
  • Tortoise Investment Management first reported a position in Ligand Pharmaceuticals in Q3 2024 and held it in 5 quarters.
  • Tortoise Investment Management's Ligand Pharmaceuticals position peaked at $18.1K in Q3 2025.
  • 350 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.

Based on Tortoise Investment Management's 13F filing for Q4 2025, filed 6 Feb 2026.